Overview

This trial is active, not recruiting.

Condition glioma
Treatments ly2157299, lomustine
Phase phase 1
Target TGFBR1
Sponsor Eli Lilly and Company
Start date December 2005
End date May 2012
Trial size 66 participants
Trial identifier NCT01682187, 8660, H9H-MC-JBAH

Summary

This is a study of oral LY2157299 as monotherapy and in combination with lomustine in participants with recurrent malignant glioma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
ly2157299
Administered orally
(Experimental)
LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily. Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter.
ly2157299
Administered orally
lomustine
Administered orally

Primary Outcomes

Measure
Recommended Dose for Phase 2 Studies
time frame: Time of first dose to time of last dose (estimated up to 8 years)

Secondary Outcomes

Measure
Number of Participants with Tumor Response
time frame: Time of first dose to time of last dose (estimated up to 8 years)
Biologically Effective Dose Range
time frame: Baseline, Days 1, 12, 13 of Cycle 1, Days 1 and 12 of Cycle 2 of Part A - LY2157299 as monotherapy
Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC)
time frame: Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14
Pharmacokinetics (PK): Maximum Concentration (Cmax)
time frame: Part A Cycle 1: predose, up to 6 hours on Days 1, 3, 6, 12, 13, and 14; Part A Cycle 2: predose up to 6 hours on Days 1, 12, and 13. Part B Cycle 1: predose up to 6 hours on Days 1, 6, 7, 10, 12, 13, and 14

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Have given written informed consent - Have histological or cytological evidence of relapsed malignant glioma (such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma) for which no treatment of higher priority exists - Available baseline tumor specimen is required prior to considering participant to be enrolled. The original diagnostic tumor tissue is sufficient for this inclusion criteria, but where possible, freshly obtained tumor biopsy material may be obtained - Measurable disease to allow assessment of tumor response based on radiographic assessment following Macdonald criteria and Response Evaluation Criteria In Solid Tumors (RECIST) - Have sufficient hepatic, renal, and hematological function - Have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale - Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy or other investigational therapy for at least 30 days prior to study enrollment and recovered from the acute effects of therapy - Able to swallow tablets and capsules - For females, reproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method (including intrauterine or barrier devices) during and for 3 to 6 months after the study - Male participants must be willing to use contraception during and for 3 to 6 months after the study Exclusion Criteria: - Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry - Have moderate or severe cardiac disease: - Have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension - Have documented major electrocardiogram (ECG) abnormalities at the investigator's discretion (for example, symptomatic or sustained atrial or ventricular arrhythmias, second- or third-degree atrioventricular block, bundle branch blocks, ventricular hypertrophy, or recent myocardial infarction) - Have major abnormalities documented by echocardiography with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction (LVEF) <50%, evaluation based on the institutional lower limit of normal) - Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by computerized tomography [CT] scan with contrast) - Have current acute or chronic leukemia - Women who are pregnant or lactating - Have received prior nitrosourea (including lomustine) therapy

Additional Information

Official title Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Eli Lilly and Company.